Clinical Trial Update: QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 trial of CD19 t-haNK for diffuse large B-cell lymphoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Diffuse Large B-cell Lymphoma
• Large-cell Lymphoma
• Lymphoma

Drugs mentioned

• CD19 t-haNK

Snippet

Sponsor: ImmunityBio, Inc. | Conditions: Diffuse Large B Cell Lymphoma, Large-cell Lymphoma | Phase 1 | Status: WITHDRAWN